INTRODUCTION
============

The most critical risk factor for the development of chronic obstructive pulmonary disease (COPD) is cigarette smoking.[@B1] However, only 10-20% of heavy smokers develop airway obstruction and -20-30% of COPD patients never smoke.[@B2],[@B3],[@B4],[@B5],[@B6] Moreover, previous reports of familial aggregation of COPD suggest that genetic components are likely associated with susceptibility to the development of COPD.[@B7],[@B8]

Numerous candidate genes have been reported to be associated with COPD. These genes are generally related to protease-antiprotease interaction, antioxidant effects, xenobiotic metabolism, and inflammation and immune response pathways.[@B9] One of the candidates involved in inflammation and immune reaction is the gene encoding vitamin D binding protein (VDBP, *GC*).

VDBP was first described by Hirschfeld in 1959 as a marker in gamma-globulin of human serum and characterized as a group-specific component.[@B10] In 1975, it was identified as the plasma protein that binds vitamin D.[@B11] The major role of VDBP is transporting 25-hydroxyvitamin D, the major circulating form of vitamin D, and 1,25-dihydroxyvitamin D, the most active vitamin D metabolite. However, when expressed by neutrophils, VDBP activates macrophages and augments monocyte and neutrophil chemotaxis.[@B12],[@B13],[@B14],[@B15] These roles of VDBP may contribute to the chronic inflammatory response in COPD.

*GC*, located on chromosome 4, is approximately 42 kb in size and has more than 120 reported variants.[@B16] Most of the variants are rare except three commonly recognized variants according to single nucleotide polymorphisms at rs4588 and rs7041 in exon 11: *GC1F* (A/G), *GC1S* (A/T), and *GC2* (C/G).[@B17] The association of these VDBP polymorphisms and the risk for COPD has been debated in the literature for some time.[@B9],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B24],[@B25],[@B26] *GC2* tended to be protective variants for COPD in Caucasian populations and *GC1F* tended to be risk variants for COPD in Asian populations.[@B27] However, Asian studies were conducted in the limited ethnicities, and *GC* variants were not evaluated in South Korea. Moreover, the studies were conducted in a small number of patients and the relationship with lung function decline was rarely investigated.[@B20]

The purpose of this study was to evaluate the frequencies of *GC* variants in Koreans with COPD as well as healthy subjects. We determined that certain *GC* variants are associated with a genetic susceptibility to COPD in Koreans and examined the correlation between *GC* variants and lung function in COPD patients.

MATERIALS AND METHODS
=====================

Subjects
--------

The COPD group consisting of 203 patients who were taken from the Korean Obstructive Lung Disease (KOLD) Cohort, in which patients with COPD or asthma have been enrolled from pulmonary clinics in 17 hospitals in South Korea from June 2005 to 2011, were selected for this study. The subjects were culled from a KOLD Cohort that fulfilled the following criteria: post-bronchodilator ratio of forced expiratory volume in 1 second (FEV~1~) to forced vital capacity (FEV~1~/FVC) \<0.7, over 40 years of age, smoking history of 10 or more pack-years, and no or minimal abnormality on chest radiography. The control group was selected from a community-based prospective cohort, South Korea. Among 2534 people recruited in 2006, 157 participants had a normal pulmonary function test, 10 or more pack-years of smoking history, and were over the age of 40. The study protocol was approved by the Institutional Review Boards of the 17 hospitals included in the KOLD Cohort and the community-based prospective cohort for control group, and informed written consent was obtained from all patients.

Pulmonary function testing
--------------------------

Spirometry was performed according to American Thoracic Society/European Respiratory Society guidelines. Airway obstruction is defined by Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria as FEV~1~/FVC ratio of \<0.7. The severity of the disease was based on the percent predicted FEV~1~ in accordance with GOLD criteria.[@B28] For COPD patients, pulmonary function tests (PFTs) were performed at follow-up visits annually and PFT was performed at least two times in 178 (87.6%) with an average of 3.7 times during the study.

Genotyping
----------

For genotyping *GC*, DNA was extracted from blood and polymerase chain reaction (PCR) was performed followed by restriction fragment-length polymorphism analysis. The region that includes the two point mutation sites in exon 11 (Glu/Asp 416 and Thr/Lys 420) was amplified.[@B27] We used upstream primer of 5\'TAATGAGCAAATGAAAGAAG3\' and downstream primer of 5\'TGAGTAGATTGGAGTGCATAC3\'.[@B20],[@B25] The final PCR product was a fragment of 462 base pairs (bp).

PCR was performed in a thermal cycler (DNA Thermal Cycler; Perkin Elmer Cetus; Norwalk, CT, USA). PCR reactions were carried out in a volume of 40 µL containing 100 ng DNA, 1.5 mM MgCl~2~, 10 mM Tris Cl (pH 8.3), 40 mM KCl, 4% dimethyl sulphoxide, 0.2 mL of each dNTP (Amersham Biosciences KK; Tokyo, Japan), 0.5 µmol/L of each primers, and 3.75 units of Taq DNA polymerase (Bioneer, Daejeon, Korea). After amplification, PCR products were digested with Hae III (Toyobo; Osaka, Japan), or Eco T14 I (Takara Bio; Otsu, Japan) at 37℃ overnight. Hae III cuts the *GC1S* product into two bands of 295 bp and 167 bp, whereas Eco T14 I cuts the *GC2* product into two bands of 302 bp and 156 bp. *GC1F* PCR product remains uncut by either enzyme ([Fig. 1](#F1){ref-type="fig"}).

Definitions
-----------

Rapid decliners were defined as those with a decrease in FEV~1~ ≥3.0% predicted/yr and non-decliners as those with an increase in FEV~1~ ≥0% predicted/yr.[@B24]

Data analysis
-------------

Differences in distribution and frequency of variants and genotypes among the groups were examined by chi-squared test. Normally distributed variables are presented as means±standard deviations, and non-normally distributed variables are presented as medians (interquartile range). Genotype frequencies and Hardy-Weinberg equilibrium (HWE) for the *GC* between COPD and control groups were determined by chi-squared test. Statistical inference of the genotype effect on FEV~1~ was conducted with the linear mixed model to consider correlation between annually measured FEV~1~. Statistical inference of the genotype effect on FEV~1~ at the 0.05 significance level was conducted with the linear mixed model to consider correlation between repeated measures. COPD patients and control subjects were included for linear mixed model and COPD indicator was included as dummy variable to explain their mean differences. We also found the heteroscedasticity between COPD patients and control subjects, and a different variance-covariance matrix was applied. The optimal correlation structure between repeated observations was selected with the likelihood ratio test based on the restricted maximum likelihood method and the unstructured correlation format was chosen.[@B29],[@B30] Age, sex, height, pack-year, and their interactions were included as covariates and the significant interactions were selected with likelihood ratio test based on the maximum likelihood method. Marginal effects are all included in our final model. In all analyses, a *p*-value \<0.05 was deemed to be statistically significant.

RESULTS
=======

Population characteristics
--------------------------

All baseline characteristics of the study population are summarized in [Table 1](#T1){ref-type="table"}. Both groups exhibited a similar gender distribution of significant male dominance. COPD patients were also of more advanced age than the control population. The number of current smokers was higher in controls compared to COPD group, whereas former smokers were more prevalent in the COPD group than controls. Among COPD patients, 17 (8.4%), 101 (49.8%), 73 (36.0%), and 12 (5.9%) patients were classified as GOLD class I, II, III and IV.

Genotyping
----------

The frequency of each variant and genotype in COPD and control groups are compared in [Table 2](#T2){ref-type="table"}. Each of the investigated single nucleotide polymorphisms (rs4588 and rs7041) was in HWE in the controls (all *p*\>0.05). Frequencies of *GC1F*, *GC1S*, and *GC2* variants in COPD patients were 46.1%, 21.4%, and 32.5%, respectively, and 42.0%, 29.0%, and 29.0%, in controls, respectively. *GC1S* variant was more frequent in controls than COPD patients (29.0% vs. 21.4%; *p*=0.020). There were no significant differences in sex ratio, age, and smoking history between the different types of genotypes. Genotype 1F-2 was most common in both groups and genotype 1S-1S was significantly more frequent in control than COPD (8.3% vs. 3.4%; *p*=0.047).

Comparison between rapid decliners and non-decliners
----------------------------------------------------

[Table 3](#T3){ref-type="table"} shows the comparison of characteristics and genotypes between 62 rapid decliners and 74 non-decliners. Baseline characteristics including sex ratio, age, and spirometry data were not different between the two groups. In comparing the variants and genotypes, *GC1S* variant was more frequently observed in non-decliners (26.4% vs. 16.1%, *p*=0.042) and genotype 1F-2 was more frequently observed in rapid decliners (37.1% vs. 21.6%, *p*=0.047).

Parameters associated with FEV~1~ according to linear mixed model analysis
--------------------------------------------------------------------------

The difference in FEV~1~ between different genotypes was investigated by linear mixed model analysis including sex, age, height, and pack-years of smoking as shown in [Table 4](#T4){ref-type="table"}. FEV~1~ was 2.649 L lower in COPD compared to controls (*p*\<0.001), 0.345 L lower in females than in males (*p*=0.014), and 0.033 L lower per year of age (*p*\<0.001). Moreover, as stature increased by 1 cm, FEV~1~ also increased by 0.027 L (*p*\<0.001). Among the different genotypes, subjects with genotype 1S-1S had 0.427 L higher FEV~1~ than those with other genotypes (*p*=0.029). The genotype/smoking pack-year interaction was found to be particularly significant among subjects with genotype 1S-1S; FEV~1~ decreased by 0.014 L per smoking pack-year (*p*=0.001).

According to the linear mixed model analysis, the final equations were obtained as follows: FEV~1~=0.488-0.033×age (year)+0.027×height (cm)-0.012×smoking pack-years+0.427 (for control group with genotype 1S-1S); FEV~1~=0.488-0.033×age (year)+0.027×height (cm)+0.002×smoking pack-years (for control group without genotype 1S-1S); FEV~1~=0.488-0.013×age (year)+0.027×height (cm)-0.012×smoking pack-years-1.711 (for COPD group with genotype 1S-1S); FEV~1~=0.488-0.013×age (year)+0.027×height (cm) +0.002×smoking pack-years-2.649 (for COPD group without genotype 1S-1S).

DISCUSSION
==========

The potential association of polymorphisms in *GC* with the risk of COPD and lung function was investigated for the first time in a Korean population. Subjects with *GC1S* variant and genotype 1S-1S were more commonly observed in control than in COPD. Moreover, *GC1S* variant was more frequent in non-decliners than in rapid decliners among COPD. According to the linear mixed model analysis, genotype 1S-1S showed higher initial FEV~1~ than other genotypes. However, FEV~1~ decreased more in 1S-1S patients than in other genotypes as smoking pack-years increased.

Frequencies of the different genotypes previously discussed vary based on ethnicity ([Table 4](#T4){ref-type="table"}). In the Japanese population, *GC1F* variant is most commonly observed, comprising approximately half of the population (0.58-0.61 in COPD and 0.48-0.49 in control). In Caucasians, *GC1S* variant is most common with a frequency of 0.53-0.61 in COPD and 0.58 in controls.[@B19],[@B20] The Korean population in this study showed a similar distribution to the Japanese population.[@B18],[@B25] *GC1F* variant was most frequent in COPD (0.46) and control group (0.42), although its frequency was smaller than that in a Japanese population.

Prior investigations have demonstrated different results regarding the association between polymorphisms in *GC* and risk of COPD; however, studies focusing on Asian populations have only been in Chinese and Japanese cohorts. Ishii, et al.[@B19] reported *GC1F* variant and genotype 1F-1F were significantly higher in COPD than in control (85.7% vs. 75.6%, *p*=0.036; 36.5% vs. 20.7%, *p*=0.035) in a Japanese population. In another Japanese study, Ito, et al.[@B20] reported a higher frequency of genotype 1F-1F in COPD patients than in controls (32% vs. 17%, *p*=0.014). In a Chinese population, Lu, et al.[@B23] suggested that *GC1F* variant and genotype 1F-1F were risk factors for COPD (55.8% vs. 40.4%, *p*=0.018; 33.3% vs. 11.5%, *p*=0.005). In a Canadian Caucasian population, Horne, et al.[@B18] reported GC2 variant and genotype 2-2 were less frequently observed in a COPD group. Relative risks of genotype 2-2, 2-1S, 2-1F for COPD were 0.8, 0.7, and 0.5, respectively. Moreover, they stated that *GC1F* variant was a significant risk factor for COPD (relative risk=4.8). Schellenberg, et al.[@B25] were able to confirm that genotype 2-2 was protective against COPD (odds ratio=0.17, 95% CI 0.03-0.83). In an American population, Kueppers, et al.[@B31] also showed genotype 2-2 as a protective factor for COPD (relative risk=0.2). Despite all these reports, several studies have failed to show association between GC polymorphisms and COPD.[@B24],[@B32]

Most of these studies were conducted with a cross-sectional design, such that only the frequencies of certain *GC* polymorphisms were compared between COPD and control groups. A few studies demonstrated the relationship of *GC* polymorphisms with lung function decline through longitudinal analysis.[@B20],[@B24] Although Sandford, et al.[@B24] reported no difference between fast decliners and non-decliners, Ito, et al.[@B20] showed that *GC1F* variant still is a risk factor for rapid lung function decline even in a longitudinal analysis. However, in the latter, the number of subjects with available follow-up lung function data was small and the follow-up duration of 1 year may not be long enough to accurately analyze lung function decline. The size of the subjects in our study is too small to demonstrate the effect of *GC* polymorphisms on COPD and lung function. However, we have analyzed all the follow-up lung function data of subjects with longer duration of follow-up using a linear mixed model.

There are several possible explanations for the association between *GC* polymorphisms and lung function decline. The major role of VDBP is to bind and transport vitamin D. Vitamin D is essential for maintaining normal bone growth and calcium homeostasis, but it also contributes to immune modulation. Epidemiologic research has demonstrated vitamin D deficiency is associated with many types of chronic disease and these chronic diseases are all co-morbidities of COPD. Moreover, vitamin D deficiency is a risk factor of lung function decline in COPD through dysregulation of adaptive and innate immunity. Janssens, et al.[@B33] reported that vitamin D deficiency correlates with the severity of COPD and certain types of *GC* polymorphisms are associated with reduced vitamin D levels.[@B34] Moreover, VDBP enhances the chemotactic activity of C5-derived peptides on human neutrophils and monocytes. Enzymatic processing of the carbohydrate side-chain of VDBP transforms the molecule into a potent macrophage-activating factor (MAF). In turn, VDBP-MAF stimulates macrophage activity. Recently, Wood, et al.[@B35] reported that the *GC2* genotype is less efficient at converting VDBP to VDBP-MAF.

However, there are limitations to the present study. First, the sex and age between the two groups were not exactly matched. The COPD group was comprised of slightly more males and older subjects compared to the control group. Though the effect of age was adjusted for by statistical methods, some of the younger control subjects may yet develop COPD in the future. Moreover, cautious interpretation of the results is needed because of the relatively small sample size, especially *GC1S* variant and genotype 1S-1S. Analysis of lung function in control subjects was limited because follow-up lung function data were only available in five subjects of control group. Finally, vitamin D status is also an important factor in investigating the association of *GC* genotypes and lung function, but it was not included in this study.

In conclusion, this study suggested that *GC* polymorphisms might be associated with COPD and lung function in Korean population. Subjects with *GC1S* variant and genotype 1S-1S were more common in control than in COPD. *GC1S* variant was more frequent in non-decliners than in rapid decliners among COPD. The subjects with genotype 1S-1S showed higher initial FEV~1~ than other genotypes. However, genotype 1S-1S was associated with lower lung function in the context of cigarette smoking. As the amount of smoking in subjects with genotype 1S-1S increases, decrease in lung function became more pronounced. To elucidate the relationship of *GC* polymorphisms and lung function in COPD, additional studies with larger number of subjects are required.
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COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity.

^\*^Data are presented as numbers (percentages) for categorical variables. Continuous variables are presented as means±standard deviations or median (interquartile range).
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